{"product_id":"management-of-complex-treatment-resistant-psychotic-disorders-paperback-9781108965682","title":"Management of Complex Treatment-resistant Psychotic Disorders (Paperback \/ softback) 9781108965682","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eManagement of Complex Treatment-resistant Psychotic Disorders\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eAn essential handbook providing practical guidance and medication advice on the effective management and treatment of psychotic disorders.\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eMichael Cummings (Edited by), Stephen Stahl (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781108965682, Cambridge University Press\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePaperback \/ softback, published 22 July 2021\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e538 pages\u003cbr\u003e22.7 x 13.7 x 2.3 cm, 0.88 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e'The book is clearly useful for medical students, residents, and young psychiatrists.' Michael Easton, Doody's Notes\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eThis full-color, practical handbook provides a concise, evidence-based psychopharmacological approach to the management of complex treatment-resistant psychotic disorders. Part I focuses uniquely on topics and strategies relevant to treating this challenging patient population. These approaches go beyond standard guidelines while adhering to research and clinically derived data. Part II provides a concise array of information regarding those classes of medications most commonly used when treating complex treatment-resistant psychotic disorders. Each medication guide contains sections including mechanisms of action, typical treatment response, monitoring, dosing and kinetics, medications to avoid in combination\/warnings, and take-home pearls. Part III offers tips in brief appendix chapters for managing common issues ranging from loading lithium and valproic acid to the treatment of acute psychomotor agitation. An essential resource for psychiatrists, forensic clinicians, psychiatric trainees, and all mental health professionals involved with, or interested in, the treatment of challenging psychotic disorders.\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePart I. Treatment Strategies: 1.01. Approaches to positive Psychotic symptoms\u003cbr\u003e 1.02. Use of plasma levels in Antipsychotic and Mood Stabilizer treatment\u003cbr\u003e 1.03. Advantages of long-acting injectable Antipsychotics\u003cbr\u003e 1.04. Approach to Schizophrenia Spectrum treatment-resistant patients\u003cbr\u003e 1.05. Approach to depressed or suicidal Schizophrenia Spectrum patients\u003cbr\u003e 1.06. Approach to persistent aggression and violence in Schizophrenia Spectrum Disorders\u003cbr\u003e 1.07. Approach to treatment of Bipolar Diathesis in Schizophrenia Spectrum patients\u003cbr\u003e 1.08. Approach to Anxiety in Schizophrenia Spectrum patients\u003cbr\u003e 1.09. Approach to Insomnia and Sleep Disturbance in Schizophrenia Spectrum disorders\u003cbr\u003e 1.10. Approach to Psychosis in children and adolescents\u003cbr\u003e 1.11. Electro-convulsive therapy and other Non-pharmacological treatments\u003cbr\u003e 1.12. Approach to substance use disorders in Schizophrenia Spectrum Disorders\u003cbr\u003e 1.13. Approaches to Behavioral Disturbances and Dementia and TBI patients\u003cbr\u003e Part II. Medication Reference Tables: First-generation (Typical) Antipsychotics: 2.01. Chlorpromazine\u003cbr\u003e 2.02. Fluphenazine\u003cbr\u003e 2.03. Haloperidol\u003cbr\u003e 2.04. Loxapine\u003cbr\u003e 2.05. Perphenazine\u003cbr\u003e 2.06. Thiothixene\u003cbr\u003e 2.07. Trifluoperazine\u003cbr\u003e Second-generation (Atypical) Antipsychotics: 2.08. Asenapine\u003cbr\u003e 2.09. Clozapine\u003cbr\u003e 2.10. Iloperidone\u003cbr\u003e 2.11. Lumateperone\u003cbr\u003e 2.12. Lurasidone\u003cbr\u003e 2.13. Olanzapine\u003cbr\u003e 2.14. Paliperidone\u003cbr\u003e 2.15. Quetiapine\u003cbr\u003e 2.16. Risperidone\u003cbr\u003e 2.17. Ziprasidone\u003cbr\u003e Dopamine Partial Agonist Antipsychotics (Arias): 2.18. Aripiprazole\u003cbr\u003e 2.19. Brexpiprazole\u003cbr\u003e 2.20. Cariprazine\u003cbr\u003e Medications for Motor\/Neurologic Adverse Effects: 2.21. Amantadine\u003cbr\u003e 2.22. Benztropine\u003cbr\u003e 2.23. Diphenhydramine\u003cbr\u003e 2.24. Trihexyphenidyl\u003cbr\u003e Mood Stabilizers: 2.25. Carbamazepine\u003cbr\u003e 2.26. Lamotrigine \u003cbr\u003e 2.27. Lithium\u003cbr\u003e 2.28. Valproic Acid\u003cbr\u003e Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants: 2.29. Citalopram\u003cbr\u003e 2.30. Escitalopram\u003cbr\u003e 2.31. Fluoxetine\u003cbr\u003e 2.32. Fluvoxamine\u003cbr\u003e 2.33. Paroxetine\u003cbr\u003e 2.34. Sertraline: SSRI\/5HT-1 Partial Agonist Antidepressants: 2.35. Vilazodone\u003cbr\u003e 2.36. Vortioxetine\u003cbr\u003e Serotonin\/Norepinephrine Reuptake Inhibitor (SNRI) Antidepressants\u003cbr\u003e 2.37. Desvenlafaxine\u003cbr\u003e 2.38. Duloxetine\u003cbr\u003e 2.39. Levomilnacipran\u003cbr\u003e 2.40. Venlafaxine\u003cbr\u003e Mixed Mechanism Antidepressants: 2.41. Bupropion\u003cbr\u003e 2.42. Mirtazapine\u003cbr\u003e 2.43. Trazodone\u003cbr\u003e Tricyclic Antidepressants: 2.44. Amitriptyline\u003cbr\u003e 2.45. Clomipramine\u003cbr\u003e 2.46. Desipramine\u003cbr\u003e 2.47. Doxepin\u003cbr\u003e 2.48. Imipramine\u003cbr\u003e 2.49. Nortriptyline\u003cbr\u003e Monoamine Oxidase Inhibitor (MAOI) Antidepressants: 2.50. Isocarboxazid\u003cbr\u003e 2.51. Moclobemide\u003cbr\u003e 2.52. Phenelzine\u003cbr\u003e 2.53. Transdermal Segeliline\u003cbr\u003e 2.54. Tranylcypromine\u003cbr\u003e Anxiolytics: 2.55. Alprazolam\u003cbr\u003e 2.56. Buspirone\u003cbr\u003e 2.57. Clonazepam\u003cbr\u003e 2.58. Diazepam\u003cbr\u003e 2.59. Hydroxyzine\u003cbr\u003e 2.60. Lorazepam\u003cbr\u003e Sedatives: 2.61. Diphenhydramine\u003cbr\u003e 2.62. Eszopiclone\u003cbr\u003e 2.63. Hydroxyzine\u003cbr\u003e 2.64. Lorazepam\u003cbr\u003e 2.65. Oxazepam\u003cbr\u003e 2.66. Temazepam\u003cbr\u003e 2.67. Zaleplon\u003cbr\u003e 2.68. Zolpidem\u003cbr\u003e Circadian Regulators: 2.69. Melatonin\u003cbr\u003e 2.70. Ramelteon\u003cbr\u003e 2.71. Tasimelteon\u003cbr\u003e Stimulants: 2.72. Atomoxetine\u003cbr\u003e 2.73. Dextroamphetamine\u003cbr\u003e 2.74. Lisdexamphetamine\u003cbr\u003e 2.75. Methylphenidate\u003cbr\u003e 2.76. Mixed Amphetamine Salts: Histaminic Stimulants: 2.77. Armodafinil\u003cbr\u003e 2.78. Modafinil\u003cbr\u003e Cognitive Agents: 2.79. Dextromethorphan\/quinidine\u003cbr\u003e 2.80. Donepizil\u003cbr\u003e 2.81. Galantamine\u003cbr\u003e 2.82. Memantine\u003cbr\u003e 2.83. Rivastigmine\u003cbr\u003e Alpha2-adrenergic Agonists: 2.84. Clonidine\u003cbr\u003e 2.85. Guanfacine\u003cbr\u003e Appendices: 3.01. Optimal Antipsychotic Plasma Concentration Ranges\u003cbr\u003e 3.02. Optimal Mood Stabilizer Plasma Concentration Ranges\u003cbr\u003e 3.03. Formulas for QT Interval Correction\u003cbr\u003e 3.04. Common Cytochrome P-450 Inducers and Inhibitors\u003cbr\u003e 3.05. Management of Constipation\u003cbr\u003e 3.06. Child-Pugh Hepatic Function Scoring\u003cbr\u003e 3.07. Loading of Lithium and Valproic Acid\u003cbr\u003e 3.08. Treatment of Prolactin Elevation\u003cbr\u003e 3.09. A Select List of Foods High in Tyramine\u003cbr\u003e 3.10. Medications that Present Risk for Serotonin Syndrome when Combined with MAOIs\u003cbr\u003e 3.11. Selected Treatment of Psychomotor Agitation.\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Psychiatry [\u003ca title=\"See our other books on Psychiatry\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Psychiatry%20%5BMMH%5D%22\"\u003eMMH\u003c\/a\u003e], Pharmacology [\u003ca title=\"See our other books on Pharmacology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Pharmacology%20%5BMMG%5D%22\"\u003eMMG\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Cambridge University Press","offers":[{"title":"Default Title","offer_id":46000142811416,"sku":"9781108965682","price":39.59,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/products\/9781108965682i.jpg?v=1696728170","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/management-of-complex-treatment-resistant-psychotic-disorders-paperback-9781108965682","provider":"Freshly Printed Books","version":"1.0","type":"link"}